Tesamorelin / Ipamorelin
Tesamorelin and Ipamorelin blend (approved GHRH analogue plus ghrelin mimetic)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Tesa/Ipa, Tesamorelin with Ipamorelin, The clinic blend
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is the clinic version of the growth hormone blend. One half is a real approved drug. It is sold as Egrifta and it takes belly fat off. The other half is a peptide with one human trial, and that trial missed. Nobody has ever tested the two together. A common vial is 5 mg of each.
What people take it for
- Losing belly fat, the deep kind around the organs.
- Better sleep.
- Holding muscle while losing fat.
- Sharper thinking, because the approved half has a small brain study behind it.
What the trials actually showed
Split this page in two. The approved half is the real thing. In a trial of 412 people, 2 mg a day for 26 weeks cut deep belly fat by 15.2 percent. The dummy group gained 5.0 percent. A bigger look at 806 people found the same result, and skin fat did not change. A different trial gave 152 older adults 1 mg a day for 20 weeks. Thinking improved a bit, mostly on planning tasks, and IGF-1 went up 117 percent. The other half has one human trial. It went to 117 people after bowel surgery and did not beat a dummy shot. Now the blend. Nobody has tested it. And here is the trap. The only dose that ever produced the belly fat result is 2 mg a day. On a 5 and 5 vial, drawing 2 mg of the good half also gives you 2 mg of the other one. People who take that second peptide alone use about a tenth of that. Nobody has tested that dose in anyone. So most blend plans cut back to 1 mg instead. That fixes the second peptide and leaves you at half the dose the belly fat result came from. Either way, one half of the vial is off the dose its own evidence sits on.
What people report
Reports, not trial results
The good
- Belly fat coming off over two to three months. The approved half does have trial data for this.
- Better sleep in the first few weeks, which people credit to the second peptide.
- Clothes fitting better even when the scale barely moves.
The bad
- Swollen hands, ankles and face, and stiff mornings. This shows up in the drug's own trial data, not just on forums.
- Aching joints and muscles.
- Blood sugar creeping up. Clinics check this for a reason, and the reason is trial data.
- Tingling or numb fingers.
- A sore red spot from a daily shot.
- You cannot drop one half. If your glucose climbs, you cut both or stop both, and you never learn which one caused it.
Where these come from: The swelling, joint pain and blood sugar effects come from the approved drug's own trial safety data. The sleep reports and the before and after stories come from clinic write ups and peptide forums, and there is no trial of the blend behind any of them. Two 2026 medical reviews of peptides sold straight to patients both flag the placebo effect as a real part of what users report.
My bottom line
One half of this vial is a real drug with 806 patients behind it. The other half is riding on its name. If you want the drug, get the drug on its own, at the dose the trial used, with a doctor watching your blood sugar.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The clinic version of the growth hormone blend, pairing the one GHRH analogue with FDA approval against 806 patients of Phase 3 data with a ghrelin mimetic whose single human trial missed its endpoint. No study has tested the two together. On the common 5 mg plus 5 mg vial, reaching the 2 mg tesamorelin dose that produced the approved result also delivers 2 mg of ipamorelin, roughly seven to ten times the dose ipamorelin is used at alone.
This is the blend that gets prescribed rather than shipped in a plain box, and it is the one where the gap between component evidence and blend evidence is widest. Tesamorelin is a stabilised GHRH analogue approved as Egrifta. In the pivotal 412-patient trial, 26 weeks of 2 mg daily cut visceral fat by 15.2 percent against a 5.0 percent increase on placebo, and a pooled analysis of 806 patients across both Phase 3 trials found visceral fat fell 24 square centimetres against a 2 square centimetre rise on placebo with no change in subcutaneous fat. That is a real drug with a real result at a defined dose. Ipamorelin has one published human trial. In 117 bowel resection patients it was well tolerated and did not significantly shorten time to a first tolerated meal, 25.3 hours against 32.6 hours on placebo.
The combination has never been studied. Not in a trial, not in a case series, not in an animal model. What is sold is a compounded or grey-market mixture in one of two common configurations: 5 mg tesamorelin with 5 mg ipamorelin, which is half of each by mass, or 10 mg tesamorelin with 3 mg ipamorelin, which is about 77 percent tesamorelin and 23 percent ipamorelin. By molecule count an equal-mass vial is nothing like equal. Tesamorelin weighs 5,135.9 Da and ipamorelin weighs 711.85 Da, so a 1:1 mass blend delivers about 7.2 ipamorelin molecules for every tesamorelin molecule.
Here is the specific problem the fixed ratio creates, and it is sharper on this blend than on any other page in this batch. The only tesamorelin dose that has ever produced the visceral fat result is 2 mg daily. On a 5 plus 5 vial reconstituted in 2 mL you have 2.5 mg per mL of each, so 2 mg of tesamorelin is a 0.8 mL draw, which is 80 units on an insulin syringe, and it carries 2 mg of ipamorelin with it. Ipamorelin protocols outside a blend generally run 200 to 300 micrograms. Nobody has published what 2 mg of ipamorelin daily does to a person. On the 10 plus 3 vial the same 2 mg of tesamorelin arrives with 600 micrograms of ipamorelin, still two to three times the usual single-peptide dose.
The way most blend protocols avoid that is to dose 1 mg of tesamorelin instead of 2 mg, which brings the ipamorelin down to 500 to 1,000 micrograms and brings the tesamorelin down to half the approved dose. The 1 mg dose has its own human data, in a different setting: a 20-week trial in 152 adults aged 55 to 87 found a favourable effect on cognition concentrated in executive function and raised IGF-1 by 117 percent within the physiological range. It did not produce the visceral fat result, because that is not what it was testing. Whichever way the blend is dosed, one of the two components is off the dose that its evidence sits on.
Mechanism of action
Tesamorelin activates the pituitary GHRH receptor, raising the amplitude of endogenous growth hormone pulses while preserving hypothalamic feedback, which is the property that let it reduce visceral fat without the effects of giving growth hormone directly. Ipamorelin activates the ghrelin receptor GHS-R1a on the same cell, a separate pathway that also releases growth hormone and reduces somatostatin tone. The proposed rationale is that two different receptors produce a larger pulse than either alone, which is true of the GHRH plus GHRP class in acute human testing and untested for this specific pair.
Human evidence
One component has some of the strongest human evidence in this database and the other has a single null trial. Neither of those facts is evidence about the blend, which has never been given to a person in a published study.
- Tesamorelin 2 mg daily, 412 patients, 26 weeks: visceral fat down 15.2 percent against a 5.0 percent rise on placebo.
- Tesamorelin, 806 patients pooled across two Phase 3 trials: visceral fat down 24 square centimetres against a 2 square centimetre rise on placebo, with subcutaneous fat unchanged.
- Tesamorelin 1 mg daily, 152 older adults, 20 weeks: favourable cognition effect concentrated in executive function, IGF-1 up 117 percent within the physiological range.
- Ipamorelin, 117 bowel resection patients: well tolerated, no significant shortening of time to a first tolerated meal against placebo.
- GHRH plus GHRP-6 in 20 patients roughly doubled the acute growth hormone peak compared with the secretagogue alone.
What this does not tell you: Every tesamorelin number above comes from people with HIV-associated lipodystrophy or from older adults in a cognition trial. None of it comes from healthy adults taking it for body composition, and none of it was produced in the presence of ipamorelin. The ipamorelin trial was intravenous and short. Nothing here establishes a dose for the pair, a ratio for the pair, or the stability of the pair in one vial, and nothing addresses the central practical fact that on a 1:1 vial you cannot reach the proven tesamorelin dose without an unstudied ipamorelin dose.
Reading the research record
This page exists because the blend borrows credibility that belongs to only one of its two halves. Tesamorelin's approval, its 806-patient dataset and its NEJM publication are genuine, and they are frequently presented as though they apply to a vial that also contains something else at seven times the molar concentration. They do not. Separating what is established for tesamorelin from what is claimed for tesamorelin plus ipamorelin is the whole job of this page.
The second thing worth stating plainly is that the tesamorelin result was measured in a specific population with a specific problem. Visceral fat in HIV-associated lipodystrophy is a distinctive condition, and the FDA labelling reflects that. Whether a healthy 45-year-old loses visceral fat on tesamorelin has not been tested to the same standard, with or without a secretagogue alongside it.
And the same fixed-ratio trap applies here as on every blend page. Tesamorelin's known effects include fluid retention, joint pain and a rise in blood glucose. If any of those appear, the only move a blend allows is lowering both peptides or stopping entirely. You cannot keep the tesamorelin and drop the ipamorelin, or the reverse, and you can never find out which one was responsible.
The evidence, charted
Fig. 1 · evidence composition
5of 6 citations (83%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 6 distinct years, 2002 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Not approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2007
Metabolic effects of a growth hormone-releasing factor in patients with HIV
412 patients with HIV and abdominal fat accumulation. Twenty-six weeks of tesamorelin at 2 mg daily reduced visceral adipose tissue by 15.2 percent against a 5.0 percent increase on placebo, with lower triglycerides. This is tesamorelin alone at 2 mg. No ipamorelin was given, and 2 mg daily is the dose the approval rests on.
New England Journal of Medicine - Human2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
806 patients pooled across both Phase 3 trials. Visceral fat fell 24 square centimetres at week 26 against a 2 square centimetre rise on placebo, a treatment effect of minus 15.4 percent, with no change in subcutaneous fat. The largest dataset on either component of this blend, and it is tesamorelin monotherapy.
Journal of Clinical Endocrinology and Metabolism - Human2012
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
152 adults aged 55 to 87, of whom 66 had mild cognitive impairment. Twenty weeks of tesamorelin at 1 mg daily had a favourable effect on cognition, P equal to 0.03, concentrated in executive function, and raised IGF-1 by 117 percent within the physiological range. Note the dose: 1 mg, which is half the dose that produced the visceral fat result, and this trial did not measure visceral fat.
Archives of Neurology - Human2014
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Phase 2 randomised controlled trial in 117 surgical patients. Intravenous ipamorelin was well tolerated but did not significantly shorten time to a first tolerated meal against placebo, 25.3 hours versus 32.6 hours, P equal to 0.15. This is the entire published human record for the ipamorelin half of the blend, and it is a null result on a different question.
International Journal of Colorectal Disease - Human2002
Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test
Twenty patients. Mean peak growth hormone was 25.7 micrograms per litre on GHRP-6 alone and 54.7 micrograms per litre when GHRH was added, in the growth hormone sufficient group. The class principle behind pairing a GHRH analogue with a ghrelin mimetic, demonstrated as a one-off intravenous diagnostic test with GHRH and GHRP-6, not with tesamorelin and ipamorelin.
European Journal of Endocrinology - Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Narrative review covering tesamorelin, ipamorelin, CJC-1295, sermorelin and others sold direct to patients. Many unapproved peptides show favourable outcomes in animal models while rigorous human safety data are scarce, and the authors treat the placebo effect and social media amplification as active mediators of reported peptide benefit.
Sports Medicine
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Visible loss of abdominal fat over two to three months, which is the effect people buy this blend for and which tesamorelin alone does have trial data behind.
- Better sleep in the first weeks, attributed by users to the ipamorelin.
- Swelling and puffiness in the hands, ankles and face, and morning stiffness. Fluid retention is a known tesamorelin effect and appears in its labelling.
- Joint and muscle aches.
- Rising fasting glucose or HbA1c on follow-up bloods, which is a documented concern with growth hormone axis stimulation and is the reason clinics check it.
- Tingling or numbness in the fingers.
- Injection site redness, a common report given the daily subcutaneous schedule.
Sources: Fluid retention, arthralgia and glucose effects appear in the tesamorelin Phase 3 safety data and its FDA labelling, which is trial-derived. The sleep reports, the timelines and the abdominal fat impressions are from clinic write-ups and peptide user forums and are not from any trial of the blend. The 2026 Sports Medicine and Frontiers in Endocrinology reviews both flag the placebo effect as a real contributor to what users report on unapproved peptides.
Frequently asked questions
Is this blend the same as the approved drug Egrifta?
No. Egrifta is tesamorelin alone, at 2 mg daily, approved for HIV-associated lipodystrophy. The blend adds a second unapproved peptide in a fixed ratio and has never been reviewed or studied as a product. The approval belongs to one ingredient, not to the vial.
How much ipamorelin am I getting if I dose the tesamorelin properly?
On a 5 mg plus 5 mg vial, too much to have been studied. Reconstituted in 2 mL you have 2.5 mg per mL of each, so the 2 mg of tesamorelin that produced the approved visceral fat result is an 80 unit draw carrying 2 mg of ipamorelin. Ipamorelin on its own is usually run at 200 to 300 micrograms. On a 10 mg plus 3 mg vial the same tesamorelin dose brings 600 micrograms of ipamorelin, still two to three times the usual.
Does the ipamorelin add anything?
Nobody has measured it in this pairing. The class principle is supported: adding a ghrelin mimetic to a GHRH roughly doubled the acute growth hormone peak in a 20-patient diagnostic study. Whether that translates into any extra fat loss, muscle or recovery on top of tesamorelin has not been tested by anyone.
Why do most blend protocols use 1 mg of tesamorelin instead of 2 mg?
Because 2 mg on a 1:1 vial drags an enormous ipamorelin dose along with it. The trade-off is that 1 mg is half the dose the visceral fat result came from. The 1 mg dose does have human data, from a cognition trial in 152 older adults, but that trial did not measure body fat.
Do I need bloodwork on this?
Fasting glucose and HbA1c are the ones that matter, because growth hormone axis stimulation can push both, and that concern comes from tesamorelin's own trial data rather than from forums. IGF-1 tells you the axis is being stimulated, which is not the same as telling you anything is improving.
Can I stop just the ipamorelin if I do not like something?
Not from one vial. That is the cost of any blend and it is the part nobody selling it mentions. Whatever side effect shows up, your only options are lower both or stop both, and you will never know which peptide caused it.